Eli Lilly | LLY - Operating Profit

Stock Price
985.08
Daily Change
7.83 0.80%
Monthly
-4.92%
Yearly
21.09%
Q1 Forecast
955.33

Eli Lilly reported $8.99B in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Abbott USD 2.25B 73M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
J&J USD 5.59B 1.81B Dec/2025
Medtronic USD 1.74B 40M Dec/2025
Merck USD 6.24B 318M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Perrigo USD 84.4M 9M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Phibro Animal Health USD 25.53M 7.83M Dec/2024
Prestige Brands USD 82.49M 2.82M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Zoetis USD 835M 101M Dec/2025